The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma
- 29 August 2010
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 284 (1) , 221-227
Abstract
Purpose To assess the significance of CA-125 regression as a prognostic indicator and predictor of optimal cytoreduction at interval debulking surgery (IDS) in women with ovarian or primary peritoneal carcinoma receiving neoadjuvant chemotherapy (NAC). Methods 63 women treated between 2004 and 2007 with neoadjuvant platinum-based chemotherapy followed by IDS were studied retrospectively. Pre-operative CA-125 values were used to calculate a regression coefficient (CA-125r) using exponential regression analysis. Outcome endpoints were overall survival (OS), time to CA-125 progression (TTC) by Rustin criteria and time to second-line treatment (TTS). Results Women with a CA-125 half-life greater than 18 days had a significantly worse OS compared to those with a half-life less than 12 days on univariate testing (HR 3.34, 95% CI 1.25–8.94, p = 0.017). On multivariable analysis, CA-125r was an independent predictor of OS [HR 1.18 (per 0.01 increase in CA-125r), 95% CI 1.01–1.40, p = 0.043]. CA-125r was independently predictive of TTC and TTS (HR 1.17, p ≈ 0.03 for each). CA-125r was also predictive of achieving optimal cytoreduction at IDS (AUC 0.756, p < 0.001). Conclusions CA-125 regression rate during pre-operative NAC is of independent prognostic value. CA-125 regression rate strongly predicts for optimal cytoreduction.Keywords
This publication has 19 references indexed in Scilit:
- Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 StudiesAnnals of Surgical Oncology, 2009
- A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinomaGynecologic Oncology, 2009
- Interval debulking surgery for advanced epithelial ovarian cancer: A Cochrane systematic reviewGynecologic Oncology, 2009
- Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric studyGynecologic Oncology, 2008
- The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulkingGynecologic Oncology, 2007
- Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2007
- Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?Annals of Oncology, 2005
- CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinomaGynecologic Oncology, 2005
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002